ResMed Inc.
HealthcareNYSE:RMD · New York Stock Exchange
+$1.37 today
Vol 0.59M · Avg 1.30M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$5.5B of revenue converted into $1.5B of net income for the selected period. Gross margin is 61.7% and net margin is 27.4%, showing how much revenue survives after costs and taxes. EPS is $10.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B +9.8% | $4.7B +10.9% | $4.2B +18.0% | $3.6B +11.9% | $3.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.1B +3.0% | $2.0B +8.7% | $1.9B +20.2% | $1.6B +14.4% | $1.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.1B +15.1% | $2.7B +12.7% | $2.4B +16.4% | $2.0B +10.1% | $1.8B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 59.4% +2.7pp | 56.7% +0.9pp | 55.8% -0.8pp | 56.6% -1.0pp | 57.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $331.3M +7.7% | $307.5M +6.9% | $287.6M +13.4% | $253.6M +12.6% | $225.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $991.0M +8.1% | $917.1M +4.9% | $874.0M +18.2% | $739.4M +10.3% | $670.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.4B +2.6% | $1.3B +9.1% | $1.2B +19.5% | $1.0B +9.5% | $935.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $235.8M +9.1% | $216.2M +10.0% | $196.5M +1.4% | $193.8M +1.2% | $191.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.9B +24.8% | $1.5B +12.9% | $1.4B +15.5% | $1.2B +6.6% | $1.1B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 37.2% +4.4pp | 32.7% +0.6pp | 32.2% -0.7pp | 32.9% -1.6pp | 34.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.7B +27.7% | $1.3B +16.6% | $1.1B +13.2% | $1.0B +10.7% | $903.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 32.7% +4.6pp | 28.2% +1.4pp | 26.8% -1.2pp | 28.0% -0.3pp | 28.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 -100.0% | $362.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $12.6M -72.4% | $45.7M -3.5% | $47.4M +112.3% | $22.3M -7.0% | $24.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$7.8M +85.8% | -$55.1M -82.4% | -$30.2M +24.1% | -$39.8M -98.9% | -$20.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.7B +32.6% | $1.3B +14.8% | $1.1B +14.7% | $960.5M +8.7% | $883.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.6% +5.6pp | 27.0% +0.9pp | 26.1% -0.8pp | 26.8% -0.8pp | 27.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $276.8M +13.5% | $243.8M +19.5% | $204.1M +12.7% | $181.0M -55.8% | $409.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.4B +37.2% | $1.0B +13.7% | $897.6M +15.2% | $779.4M +64.3% | $474.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 27.2% +5.4pp | 21.8% +0.5pp | 21.3% -0.5pp | 21.8% +6.9pp | 14.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $10 +37.6% | $7 +13.4% | $6 +14.6% | $5 +63.3% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $10 +37.4% | $7 +13.6% | $6 +14.9% | $5 +63.6% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $146.7M -0.2% | $147.0M +0.2% | $146.8M +0.5% | $146.1M +0.5% | $145.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $147.3M -0.1% | $147.6M +0.1% | $147.5M +0.3% | $147.0M +0.4% | $146.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.90B
Cardinal Health, Inc.
NYSE:CAH
$52.49B
Humana Inc.
NYSE:HUM
$45.35B
Haleon plc
NYSE:HLN
$40.37B
Agilent Technologies, Inc.
NYSE:A
$36.58B
Alcon Inc.
NYSE:ALC
$32.54B
IQVIA Holdings Inc.
NYSE:IQV
$29.94B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.56B
Mettler-Toledo International Inc.
NYSE:MTD
$22.89B
Insmed Incorporated
NASDAQ:INSM
$21.23B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RMD generate?
ResMed Inc. (RMD) reported $5.15B of revenue in fiscal 2025.
Is RMD profitable?
ResMed Inc. (RMD) reported $1.40B of net income, with a net margin of 27.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.